Spero Therapeutics (SPRO) Stock Price, News & Analysis
What Changed
Price Move History
- Daily moves over 5%
- 34 252 sessions, November 6, 2025 to November 6, 2026
- Largest daily move
- -23.8% close of June 17, 2026
- 1-year change
- -56.9% closing prices, November 6, 2025 to November 6, 2026
- 1-month change
- -13.4% closing prices, October 6, 2026 to November 6, 2026
Company Description
Company Overview
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. Its common stock trades on the Nasdaq Global Select Market under the symbol SPRO. The company focuses on next-generation medicines in immunology and inflammation for patients with serious immune-mediated diseases.
Lead Program
Spero’s lead program, SP001, is a third-generation, Fc-silent anti-CD40L monoclonal antibody. The company is advancing SP001 first in IgG4-related disease, with potential development in additional immunological and inflammatory diseases.
Spero holds an exclusive, sublicensable license from Innovent Biologics for SP001 and certain related CD40L-targeting monoclonal antibodies. The license covers research, development, manufacturing and commercialization rights in the licensed territory outside Innovent’s retained territory.
Antibiotic Asset and Licensing
Spero-developed Utebzi (tebipenem pivoxil) is an FDA-approved oral antibiotic for adults with complicated urinary tract infections, including pyelonephritis, caused by certain susceptible pathogens in patients who have limited or no alternative oral treatment option.
Spero has granted GSK an exclusive license to develop and commercialize Utebzi in all territories except certain territories in Asia, where Meiji holds development and commercialization rights. Spero has also described future Utebzi milestone and royalty payments associated with sales of the product.
Key Business Characteristics
- Sector: biopharmaceuticals.
- Primary focus: immunology and inflammation medicines for serious immune-mediated diseases.
- Core modality: monoclonal antibody development through SP001.
- Additional asset history: Spero-developed Utebzi is an approved oral antibiotic with external commercialization rights.
- Listing: common stock trades on the Nasdaq Global Select Market under SPRO.
Stock Performance
Spero Therapeutics (SPRO) closed at $1.03 on November 6, 2026. Over the past 12 months, the price has lost 56.9%.
SPRO Metrics & Rankings
Price returns through November 6, 2026. Month and year figures include the first trading day. Ranking links may use different dates.
Latest News
Spero Therapeutics has 10 recent news articles, with the latest published 4 days ago. Of the recent coverage, 3 articles coincided with positive price movement and 5 with negative movement. Key topics include conferences, earnings, earnings date. View all SPRO news →
SEC Filings
Spero Therapeutics has filed 10 recent SEC filings, including 4 Form 8-K, 2 Form 4, 1 Form 3, 1 Form EFFECT. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all SPRO SEC filings →
Financial Highlights
Spero Therapeutics generated $66.8M in revenue in FY2025, operating income reached $6.3M (9.4% operating margin), and net income was $8.6M, reflecting a 12.8% net profit margin. Diluted earnings per share stood at $0.15. The company generated -$12.6M in operating cash flow. The current ratio was 7.59, measuring current assets divided by current liabilities.
Upcoming Events
Guggenheim fireside chat
Jefferies healthcare conference
COO retirement
Innovent China Phase 2
Spero Phase 2 start
Option 25% Vesting
RSU Annual Vesting
Option initial vesting
RSU first vesting
RSU vesting schedule
Option vesting schedule
Options Monthly Vesting
Initial equity vesting
Cash runway guidance
Final equity vesting
Spero Therapeutics has 15 upcoming scheduled events. The next event, "Guggenheim fireside chat", is scheduled for November 10, 2026 (in 2 days). 1 of them is a financing or capital event, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the SPRO stock price.
Short Interest History
Short interest in Spero Therapeutics (SPRO) currently stands at 840.5 thousand shares, up 5.8% from the previous reporting period, representing 1.9% of the float. Since November 2025, short interest has increased by 36.5%.
Days to Cover History
Days to cover for Spero Therapeutics (SPRO) currently stands at 1.5 days, up 51% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 43.8%. Across the settlements charted above, it has ranged from 1.0 to 4.4 days.
SPRO Company Profile & Sector Positioning
Spero Therapeutics (SPRO) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.
Investors comparing SPRO often look at related companies in the same sector, including Gossamer Bio, Inc. (GOSS), Rani Therapeutics Holdings, Inc. (RANI), Nordicus Partners Corporation (NORD), Cingulate Inc. (CING), and Fortress Biotech, Inc. (FBIO). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate SPRO's relative position within its industry.